Status:
WITHDRAWN
Mucin Concentration in Sputum From COPD Patients During a Pulmonary Exacerbation
Lead Sponsor:
Philipps University Marburg
Conditions:
COPD
Eligibility:
All Genders
18-75 years
Brief Summary
chronic obstructive pulmonary disease (COPD) is typically associated with mucus hypersecretion in the airways. In health, mucin is the major macromolecular component and is responsible for the protect...
Detailed Description
We hypothesize that during an exacerbation the mucin amount is increasing. The aim of this study is to evaluate the molecular (mucins) and structure properties (mucin-stability) of the airway secreti...
Eligibility Criteria
Inclusion
- forced expiratory volume at one second (FEV1) \< 80%
- sputum production
- clinical likely hood of exacerbation
Exclusion
- FEV1 \> 80% or \< 30%
- increased systemic inflammation
- susceptibility of pneumonia
- need for antibiotic treatment
Key Trial Info
Start Date :
December 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01848093
Start Date
December 1 2008
End Date
July 1 2013
Last Update
November 15 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
pulmonary department, University Marburg
Marburg, Germany, 35043
2
University Marburg
Marburg, Germany